NHS National Framework Agreement for the Supply of Recombinant Von Willebrand Factor
Estimated value
—
Awarded value
—
Suppliers
1
Lots
1
Published
27 Jan 2021
Description
NHS National Framework Agreement for the supply of Recombinant Von Willebrand Factor. The framework will commence on 1 February 2021 for a period of 5 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 43 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Scope
- Reference
- CM/PHS/20/5624
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33141530
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Security of Supply | 20% | quality | — |
| Ease of use | 15% | quality | — |
| — | 65% | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded suppliers· 1 supplier
Awarded —
Other contracts from The NHS Commissioning Board (operating under the name of NHS England)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Shire Pharmaceuticals Ltd· 9
Cross-buyer view of this supplier's public-sector wins.